Eczema drug study pulled before it started
NCT ID NCT04761978
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study was designed to see how well JAK inhibitors work for adults with moderate-to-severe eczema in real-world settings. It planned to track skin improvement, itching, sleep, and side effects. However, the study was withdrawn before enrolling any participants, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JAK inhibitors
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATITIS, ATOPIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hop Claude Huriez Chu Lille
Lisle-sur-Tarn, 59037, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists hunt for biological clues to severe childhood eczema
- Can a drug calm severe eczema itch when the rash is mild? a new study investigates
- Eczema drug nemolizumab put to the vaccine test
- New eczema drug enters first human tests
- New eczema drug shows promise in Mid-Stage trial
- Eczema treatment FURESTEM-AD under Long-Term watch